Select therapeutic use:
Indications for XOPENEX HFA:
Adults and Children:
<4yrs: not established. ≥4yrs: 2 inh every 4–6hrs; or 1 inh every 4hrs may suffice.
Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and consider adding an antiinflammatory (eg, corticosteroids). Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Renal impairment; monitor (esp. in elderly). Elderly. Labor & delivery. Pregnancy. Nursing mothers.
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pain, pharyngitis, rhinitis, vomiting; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects, hypokalemia.
Vials (YES); HFA (NO)
Inhaler w. actuator (80inh)—8.4g, (200 inh)—15g; Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials; Concentrate 1.25mg/0.5mL—30 vials